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Diluted biotinylated detection antibody (50 ng / mL) was added to the plate, 0.1 mL per well, and incubated 9 7 at 37 °C for 1 h. Streptavidin and a biotinylated dsDNA amplification template were added to the plate one 9 8 by one (0.1 mL per well) and incubated at 37 °C for 0.5 h. The non-bound solution was removed, and the 9 9 wells were 1 0 0 washed five times with PBS buffer containing 0.05% Tween-20 between each binding incubation. Finally, For simplified CLISA detection, streptavidin was directly coated on 96-well plates. Then, the plate was 1 0 8 blocked with 1% BSA protein, and a biotinylated dsDNA amplification template was added to the plate (0.1 1 0 9 mL per well) and incubated at 37 °C for 0.5 h. Next, we carried out the standard CLISA method. following the protocol of the commercial kit and incubated at 37 °C for 1.5 h. Diluted biotinylated antibody 1 1 3 working solution (100 μ L/well) was added to each well and incubated at 37 °C for 1 h. Next, diluted 1 1 4 enzyme-binding working solution (100 μ L/well) was added to each well and incubated at 37 °C for 30 1 1 5 minutes in the dark. The plate was washed five times with wash solution between each binding incubation.
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Finally, a chromogenic substrate (100 μ L/well) was added and incubated at 37 °C for 15 min in the dark.
7
Stop solution (100 μ L/well) was added and the OD 450 value (within 10 min) was measured immediately after 1 1 8 mixing. Prior to carrying out the CLISA, the collateral cleavage activity of CRISPR/Cas13a and the sensitivity of 1 2 2 detecting the template RNA were first demonstrated. The CRISPR/Cas13a cleavage mechanism is shown in 1 2 3 Figure 1A . Cas13a exhibits high activity under the guidance of crRNA in the presence of a synthesized 1 2 4 target RNA. As shown in Figure 1B , the collateral cleavage activity of Cas13a can only be activated when 1 2 5 6 Cas13a/crRNA/target RNA are present simultaneously (red curve). After that, we performed the 1 2 6 CRISPR/Cas13a assay for RNA detection. As shown in Figure 1C , with the increase of target RNA 1 2 7 concentrations, the fluorescence signals enhanced gradually, and the CRISPR/Cas13a system was able to 1 2 8 detect the target RNA at as low of a concentration of 50 fM. Figure 1D shows an enlarged view of the low 1 2 9 concentration measurement curve in Figure 1C . Direct detection of RNA at a fM sensitivity level without a 1 3 0 target RNA amplification indicates that the Cas13a system is one of the most sensitive detection assays 1 3 1 currently known. Furthermore, we introduced the transcription process before the CRISPR/Cas13a assay, 1 3 2 using T7 promoter tagged DNA instead of RNA to avoid any instability problem during the procedure of 1 3 3 incubation and washing. CRISPR/Cas13a was applied to detect the DNA transcripts for further enhancement 1 3 4 of the sensitivity. As shown in Figure 1E , the T7 transcription process was added prior to the The achieved impressive sensitivity enabled us to construct a new ELISA built on the basis of a 1 5 2 transcription assisted CRISPR/Cas13a assay. As is well known, classical ELISA is a heterogeneous assay 1 5 3 format using a solid phase well plate. We next proved the feasibility of utilizing DNA transcription for this 1 5 4 purpose by using a 96-well plate. As shown in Figure 2A , streptavidin was used to directly coat the 96-well 1 5 5 plates, and then the plates were blocked with 1% BSA protein. A biotinylated DNA amplification template 1 5 6 containing a T7 promoter sequence at one end was then added to the plate. Then, the unbound DNA 1 5 7 amplification template was removed by washing. Next, transcription reaction buffer, T7 RNA polymerase, 1 5 8 and nucleotide triphosphates (NTPs) were mixed together and transcribed at 37 °C for 1 h. Finally, the 1 5 9 transcription products were detected by CRISPR/Cas13a. The fluorescence kinetic curves of each well were 1 6 0 recorded, and the fluorescence intensity increased at 50 pM of template DNA ( Figure 2B , red curve). In 1 6 1 addition, the results were also expressed by the calibration values (Δτ) in Figure 2C . In the presence of 50 After demonstrating a solid phase transcription assisted CRISPR/Cas13a assay, CLISA was developed by 1 7 5
utilizing streptavidin as a bridge to link biotinylated detection antibodies to biotinylated DNA amplification 1 7 6 templates, followed by DNA transcription to produce trigger RNA. The Cas13a system was then employed 1 7 7
to detect the product, and when a trigger RNA is present, a substantial number of signal probes can be 1 7 8
cleaved for a second signal amplification. In the CLISA, antigen-antibody binding, template transcription 1 7 9
and Cas13a detection were all performed at 37 °C.
8 0
We chose human IL-6 and human VEGF as models to validate the CLISA. Human IL-6 is an 1 8 1 inflammatory factor produced by tumor cells, T cells, and lymphocytes [25] [26] . Human VEGF is involved in the 
8 5
First, we applied CLISA to detect human IL-6. Serially diluted human IL-6 antigen and biotinylated 1 8 6 detection antibody were added sequentially to form 'antibody-antigen-antibody' complexes. After that, 1 8 7 streptavidin and the biotinylated DNA amplification template, which has been optimized as shown in Figure   1 8 8 S3, were added sequentially, resulting in binding of the DNA amplification template to the 1 8 9
'antibody-antigen-antibody' complex. Unbound templates were washed away, and then T7 RNA polymerase 1 9 0 was utilized to amplify the amplification template ( Figure 3A) . As shown in Figure 3B , it is noted that the Δ τ 1 9 1 is linear with the logarithm of human IL-6 concentrations in the range from 160 fg/ mL (8 fM) to 0.1 ng/mL showed a LOD of 12.09 pg/mL (605 fM) (blue curve). It is significant that the sensitivity of CLISA was 1 9 5
264-fold higher than that of the commercial ELISA kit. 1 9 6
10 In addition, as displayed in Figure 3C , we also applied CLISA to detect human VEGF. In the range of 160 1 9 7 fg/mL (4 fM) to 0.1 ng/mL (2.5 pM) of human VEGF, there is a linear relationship between the Δ τ and the 1 9 8 logarithm of human VEGF concentrations, with a linear regression equation of Δ τ = 6.347 lg C -9.577 (R 2 = 1 9 9 0.985) and a LOD as low as 32.27 fg/mL (0.81 fM). The commercial ELISA human VEGF kit showed a 2 0 0 LOD of 20 pg/mL (500 fM) ( Figure 3C ). This result indicated that the LOD of the CLISA was also reduced 2 0 1 by 617-fold compared to the commercial ELISA kit. Compared with the traditional ELISA, CLISA adds a transcription process to expand the target, and the 2 2 6 signal is further enhanced by the collateral cleavage activity of CRISPR/Cas13a. As a result, the sensitivity 2 2 7 of CLISA can be effectively ameliorated by two-step amplification. Furthermore, the whole process of the 2 2 8
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